Sartorius joins the community of the National Institute for Innovation in Manufacturing Biopharmaceuticals
Company hopes to contribute substantially to further optimizing and accelerating the current manufacturing processes in the biopharmaceutical industry.
Sartorius has joined NIIMBL, the National Institute for Innovation in Manufacturing Biopharmaceuticals headquartered in Newark, Delaware, USA.
The Institute, launched in 2017, is a public-private partnership and has an extensive network of academic and industry partners within the United States. Among the 115 associated members are 71 academic institutions, research laboratories, non-profit organizations and 44 companies – ranging from startups, small, medium and large companies. In addition, NIIMBL also engages several federal agencies. NIIMBL’s multi-pronged mission includes the following: accelerate biopharmaceutical manufacturing innovations, support the development of standards, enable more efficient and rapid manufacturing capabilities and establish an international, leading workforce to fundamentally strengthen the U.S. biopharmaceutical industry.
Recently NIIMBL expanded its membership offerings, allowing technology providers wider access to participation. Sartorius has joined the organization through this new affiliate membership program that permits the company to actively support the NIIMBL community activities. Furthermore, the program gives Sartorius the opportunity to influence the organization’s portfolio of existing innovation projects, give feedback to the review of new project proposals and directly sponsor one of the upcoming projects.
As a new member, Sartorius will initially learn about the NIIMBL technology project portfolio and seek opportunities to provide expertise on innovative ideas and solutions, including the application of existing technologies from its broad and unique product and technology portfolio. Examples such as single-use sensor technologies along with process analytical tools (PAT), data analytics and innovative solutions for next-generation bioprocessing will be among the key technologies Sartorius will contribute to these projects.
“We are very pleased that Sartorius is now a member of the NIIMBL organization and are excited about being able to collaborate with its members,” stated David J. Pollard, who heads the Advanced Materials & Processing unit at Sartorius Corporate Research. “I am convinced that with our access to the combined expertise of the NIIMBL community, we will be able to contribute substantially to further optimizing and accelerating the current manufacturing processes in the biopharmaceutical industry. As a leading partner of this industry, I see many highly interesting synergies that will result from the interface between Sartorius and NIIMBL members,” added Pollard.
”Sartorius’ extensive knowledge of biopharmaceutical process development equipment will be valuable to the community as we develop innovative manufacturing technologies,” stated Kelvin Lee, NIIMBL Institute Director.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance